Related Experiment Video
Updated: Apr 18, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Optimizing insulin pump therapy: the potential advantages of using a structured diabetes management program.
Karin Lange1, Ralph Ziegler, Andreas Neu
1Department of Medical Psychology, Hannover Medical School , Hannover , Germany.
Current Medical Research and Opinion
|January 20, 2015
Summary
Personalized Diabetes Management (PDM) optimizes continuous subcutaneous insulin infusion (CSII) therapy by enhancing patient-physician communication and self-management skills. This structured approach improves diabetes care despite workflow challenges.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Diabetes Management
Background:
- Continuous subcutaneous insulin infusion (CSII) therapy enhances glycemic control and treatment satisfaction in diabetes.
- Patient and clinician factors can impede optimal CSII therapy effectiveness.
- New strategies are needed to overcome obstacles in CSII therapy implementation.
Purpose of the Study:
- To adapt the Personalized Diabetes Management (PDM) model for CSII-treated patients.
- To implement a workflow structure that improves patient-physician communication.
- To support diabetes self-management skills in patients using CSII therapy.
Main Methods:
- Adapted Ceriello's PDM model for CSII therapy.
- Developed a structured workflow to enhance patient-physician communication.
- Focused on improving patients' diabetes self-management skills.
Main Results:
- The PDM process can be systematically integrated into clinical practice.
- Implementation requires workflow modification and learning PDM steps.
- Invested time is expected to yield improved workflow and patient consultations.
Conclusions:
- PDM offers a systematic, standardized process to optimize CSII therapy.
- This approach enhances communication and self-management for CSII patients.
- PDM implementation can overcome challenges in diabetes care.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:27Insulin Formulations: Types and Delivery
1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.2K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
2.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.2K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.5K
01:24Dosage Regimen: Individualization
375
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
375